Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
Background Pixatimod is a unique activator of the Toll-like Receptor 9 pathway. This phase I trial evaluated safety, efficacy and pharmacodynamics of pixatimod and PD-1 inhibitor nivolumab in immunologically cold cancers.Methods 3+3 dose escalation with microsatellite stable metastatic colorectal ca...
Main Authors: | Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Michael P Brown, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/1/e006136.full |
Similar Items
-
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
by: Gregory B Lesinski, et al.
Published: (2023-10-01) -
Long-term response with the atypical reaction to nivolumab in microsatellite stability metastatic colorectal cancer: A case report
by: Nataliya Babyshkina, et al.
Published: (2024-01-01) -
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
by: Elena Elez, et al.
Published: (2024-04-01) -
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
by: Domenico Mallardo, et al.
Published: (2023-10-01) -
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
by: Nethanel Asher, et al.
Published: (2020-08-01)